The incidence of hepatocellular carcinoma (HCC) is rapidly increasing due to the prevalence of obesity and non-alcoholic fatty liver disease, but the molecular triggers that initiate disease development are not fully understood. We demonstrate that mice with targeted loss-of-function point mutations within the AMP-activated protein kinase (AMPK) phosphorylation sites on acetyl-CoA carboxylase 1 (ACC1 Ser79Ala) and ACC2 (ACC2 Ser212Ala) have increased liver de novo lipogenesis (DNL) and liver lesions. The same mutation in ACC1 also increases DNL and proliferation in human liver cancer cells. Consistent with these findings, a novel, liver-specific ACC inhibitor (ND-654) that mimics the effects of ACC phosphorylation inhibits hepatic DNL and the development of HCC, improving survival of tumor-bearing rats when used alone and in combination with the multi-kinase inhibitor sorafenib. These studies highlight the importance of DNL and dysregulation of AMPK-mediated ACC phosphorylation in accelerating HCC and the potential of ACC inhibitors for treatment. Effective therapies are needed for treating hepatocellular carcinoma (HCC). Lally et al. report that fructose consumption and the genetic activation of acetyl-CoA carboxylase (ACC) increase hepatic de novo lipogenesis (DNL) and liver carcinogenesis. The liver-specific ACC inhibitor ND-654 is found to suppress hepatic DNL, inflammation, and HCC development.
Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma / J.S.V. Lally, S. Ghoshal, D.K. Deperalta, O. Moaven, L. Wei, R. Masia, D.J. Erstad, N. Fujiwara, V. Leong, V.P. Houde, A.E. Anagnostopoulos, A. Wang, L.A. Broadfield, R.J. Ford, R.A. Foster, J. Bates, H. Sun, T. Wang, H. Liu, A.S. Ray, A.K. Saha, J. Greenwood, S. Bhat, G. Harriman, W. Miao, J.L. Rocnik, W.F. Westlin, P. Muti, T. Tsakiridis, H.J. Harwood, R. Kapeller, Y. Hoshida, K.K. Tanabe, G.R. Steinberg, B.C. Fuchs. - In: CELL METABOLISM. - ISSN 1550-4131. - 29:1(2019 Jan 08), pp. 174-182.e5.
Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma
P. Muti;
2019
Abstract
The incidence of hepatocellular carcinoma (HCC) is rapidly increasing due to the prevalence of obesity and non-alcoholic fatty liver disease, but the molecular triggers that initiate disease development are not fully understood. We demonstrate that mice with targeted loss-of-function point mutations within the AMP-activated protein kinase (AMPK) phosphorylation sites on acetyl-CoA carboxylase 1 (ACC1 Ser79Ala) and ACC2 (ACC2 Ser212Ala) have increased liver de novo lipogenesis (DNL) and liver lesions. The same mutation in ACC1 also increases DNL and proliferation in human liver cancer cells. Consistent with these findings, a novel, liver-specific ACC inhibitor (ND-654) that mimics the effects of ACC phosphorylation inhibits hepatic DNL and the development of HCC, improving survival of tumor-bearing rats when used alone and in combination with the multi-kinase inhibitor sorafenib. These studies highlight the importance of DNL and dysregulation of AMPK-mediated ACC phosphorylation in accelerating HCC and the potential of ACC inhibitors for treatment. Effective therapies are needed for treating hepatocellular carcinoma (HCC). Lally et al. report that fructose consumption and the genetic activation of acetyl-CoA carboxylase (ACC) increase hepatic de novo lipogenesis (DNL) and liver carcinogenesis. The liver-specific ACC inhibitor ND-654 is found to suppress hepatic DNL, inflammation, and HCC development.File | Dimensione | Formato | |
---|---|---|---|
Lally HCC-AMPK-ACC-Feb 7_LB edits.pdf
Open Access dal 09/01/2020
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
449.89 kB
Formato
Adobe PDF
|
449.89 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S1550413118305217-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
3.02 MB
Formato
Adobe PDF
|
3.02 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.